Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial

Abhishek G. Sathe; Holly Tillman; Lisa D. Coles; Jordan J. Elm; Robert Silbergleit; James Chamberlain; Jaideep Kapur; Hannah R. Cock; Nathan B. Fountain; Shlomo Shinnar; Daniel H. Lowenstein; Robin A. Conwit; Thomas P. Bleck; James C. Cloyd

doi:10.1111/acem.13811

Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial

Abhishek G. Sathe, Holly Tillman, Lisa D. Coles, Jordan J. Elm, Robert Silbergleit, James Chamberlain, Jaideep Kapur, Hannah R. Cock, Nathan B. Fountain, Shlomo Shinnar, Daniel H. Lowenstein, Robin A. Conwit, Thomas P. Bleck, James C. Cloyd

Neurology

Research output: Contribution to journal › Letter › peer-review

36 Scopus citations

Original language	English (US)
Pages (from-to)	940-943
Number of pages	4
Journal	Academic Emergency Medicine
Volume	26
Issue number	8
DOIs	https://doi.org/10.1111/acem.13811
State	Published - 2019

ASJC Scopus subject areas

Emergency Medicine

Access to Document

10.1111/acem.13811

Cite this

Sathe, A. G., Tillman, H., Coles, L. D., Elm, J. J., Silbergleit, R., Chamberlain, J., Kapur, J., Cock, H. R., Fountain, N. B., Shinnar, S., Lowenstein, D. H., Conwit, R. A., Bleck, T. P., & Cloyd, J. C. (2019). Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial. Academic Emergency Medicine, 26(8), 940-943. https://doi.org/10.1111/acem.13811

Sathe, AG, Tillman, H, Coles, LD, Elm, JJ, Silbergleit, R, Chamberlain, J, Kapur, J, Cock, HR, Fountain, NB, Shinnar, S, Lowenstein, DH, Conwit, RA, Bleck, TP & Cloyd, JC 2019, 'Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial', Academic Emergency Medicine, vol. 26, no. 8, pp. 940-943. https://doi.org/10.1111/acem.13811

@article{e54235500a504e6a9b214cda61c5fcb9,

title = "Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial",

author = "Sathe, {Abhishek G.} and Holly Tillman and Coles, {Lisa D.} and Elm, {Jordan J.} and Robert Silbergleit and James Chamberlain and Jaideep Kapur and Cock, {Hannah R.} and Fountain, {Nathan B.} and Shlomo Shinnar and Lowenstein, {Daniel H.} and Conwit, {Robin A.} and Bleck, {Thomas P.} and Cloyd, {James C.}",

note = "Funding Information: From the 1Department of Experimental and Clinical Pharmacology, College of Pharmacy and Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN; the 2Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC; the 3Department of Emergency Medicine, University of Michigan, Ann Arbor, MI; and the 4Division of Emergency Medicine, Children's National Health System, and the Department of Pediatrics and Emergency Medicine, School of Medicine and Health Sciences, George Washington University Washington, DC; the 5Department of Neurology; and the 6Department of Neuroscience, Brain Institute, University of Virginia, Charlottesville, VA; 7St. George's University of London and St. George's University Hospitals NHS Foundation Trust, London, UK; 8Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; the 9Department of Neurology, University of California, San Francisco, CA; 10National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and 11Feinberg School of Medicine, Northwestern University and Rush Medical College, Chicago, IL. Received April 1, 2019; revision received May 13, 2019; accepted May 25, 2019. This work has been presented as an abstract at the London Innsbruck Colloquium on Status Epilepticus and Acute Seizures, Salzburg, Austria, April 6–8, 2017. Research reported in this publication was supported by National Institutes of Health, National Institutes of Neurological Disorders and Stroke under Awards U01NS088034, U01NS088023, U01NS056975, U01NS059041, and R01NS099653 (Clinical trials.gov identifier NCT01960075). Author contributions: AGS, LDC, HT, JJE, and JCC interpreted the data and prepared the initial draft of the manuscript; HT and JJE performed the statistical analysis; JK, RS, JC, HRC, TPB, and JJE conceived and designed the ESETT study and analysis; all authors significantly contributed to article revisions; and AGS takes responsibility for the paper as a whole. All authors were supported by the ESETT study grant from NIH/NINDS (U01NS088034). Dr. Coles reports grants from NIH/NINDS, during the conduct of the study, and personal fees from Neurelis Pharmaceuticals, grants from Sollievo, outside the submitted work. Dr. Shinnar reports grants from NINDS, during the conduct of the study, personal fees from UCB Pharma, personal fees from Eisai, and personal fees from Insys, outside the submitted work. Prof. Cock reports grants from NINDS, during the conduct of the study, and personal fees from Sage Pharmaceuticals Ltd, personal fees from Eisai Europe Ltd, personal fees from UCB Pharma Ltd, personal fees from UK Epilepsy Nurse Specialist Association, nonfinancial support from Special Products Ltd, nonfinancial support from International League Against Epilepsy, Epilepsy Certification (education) Task Force, nonfinancial support from European Academy of Neurology, and personal fees from Bial and Eisai, outside the submitted work. Dr. Fountain reports grants from NINDS, during the conduct of the study, and grants from SK Lifesciences, grants from Neurelis, grants from Takeda, grants from GW Pharma, grants from Biogen, and grants from UCB, outside the submitted work. Dr. Cloyd reports a grant from National Institute of Neurological Disorders and Stroke during the conduct of the study, personal fees from Neurelis Pharmaceuticals, and grants from Sollievo, outside the submitted work. Supervising Editor: Peter Panagos, MD. Address for correspondence and reprints: Abhishek G. Sathe, MS; e-mail: sathe134@umn.edu. ACADEMIC EMERGENCY MEDICINE 2019;26:940–943. Funding Information: We acknowledge the ESETT Data and Safety Monitoring Board. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, or the U.S. Government.",

year = "2019",

doi = "10.1111/acem.13811",

language = "English (US)",

volume = "26",

pages = "940--943",

journal = "Academic Emergency Medicine",

issn = "1069-6563",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial

AU - Sathe, Abhishek G.

AU - Tillman, Holly

AU - Coles, Lisa D.

AU - Elm, Jordan J.

AU - Silbergleit, Robert

AU - Chamberlain, James

AU - Kapur, Jaideep

AU - Cock, Hannah R.

AU - Fountain, Nathan B.

AU - Shinnar, Shlomo

AU - Lowenstein, Daniel H.

AU - Conwit, Robin A.

AU - Bleck, Thomas P.

AU - Cloyd, James C.

N1 - Funding Information: From the 1Department of Experimental and Clinical Pharmacology, College of Pharmacy and Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN; the 2Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC; the 3Department of Emergency Medicine, University of Michigan, Ann Arbor, MI; and the 4Division of Emergency Medicine, Children's National Health System, and the Department of Pediatrics and Emergency Medicine, School of Medicine and Health Sciences, George Washington University Washington, DC; the 5Department of Neurology; and the 6Department of Neuroscience, Brain Institute, University of Virginia, Charlottesville, VA; 7St. George's University of London and St. George's University Hospitals NHS Foundation Trust, London, UK; 8Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; the 9Department of Neurology, University of California, San Francisco, CA; 10National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and 11Feinberg School of Medicine, Northwestern University and Rush Medical College, Chicago, IL. Received April 1, 2019; revision received May 13, 2019; accepted May 25, 2019. This work has been presented as an abstract at the London Innsbruck Colloquium on Status Epilepticus and Acute Seizures, Salzburg, Austria, April 6–8, 2017. Research reported in this publication was supported by National Institutes of Health, National Institutes of Neurological Disorders and Stroke under Awards U01NS088034, U01NS088023, U01NS056975, U01NS059041, and R01NS099653 (Clinical trials.gov identifier NCT01960075). Author contributions: AGS, LDC, HT, JJE, and JCC interpreted the data and prepared the initial draft of the manuscript; HT and JJE performed the statistical analysis; JK, RS, JC, HRC, TPB, and JJE conceived and designed the ESETT study and analysis; all authors significantly contributed to article revisions; and AGS takes responsibility for the paper as a whole. All authors were supported by the ESETT study grant from NIH/NINDS (U01NS088034). Dr. Coles reports grants from NIH/NINDS, during the conduct of the study, and personal fees from Neurelis Pharmaceuticals, grants from Sollievo, outside the submitted work. Dr. Shinnar reports grants from NINDS, during the conduct of the study, personal fees from UCB Pharma, personal fees from Eisai, and personal fees from Insys, outside the submitted work. Prof. Cock reports grants from NINDS, during the conduct of the study, and personal fees from Sage Pharmaceuticals Ltd, personal fees from Eisai Europe Ltd, personal fees from UCB Pharma Ltd, personal fees from UK Epilepsy Nurse Specialist Association, nonfinancial support from Special Products Ltd, nonfinancial support from International League Against Epilepsy, Epilepsy Certification (education) Task Force, nonfinancial support from European Academy of Neurology, and personal fees from Bial and Eisai, outside the submitted work. Dr. Fountain reports grants from NINDS, during the conduct of the study, and grants from SK Lifesciences, grants from Neurelis, grants from Takeda, grants from GW Pharma, grants from Biogen, and grants from UCB, outside the submitted work. Dr. Cloyd reports a grant from National Institute of Neurological Disorders and Stroke during the conduct of the study, personal fees from Neurelis Pharmaceuticals, and grants from Sollievo, outside the submitted work. Supervising Editor: Peter Panagos, MD. Address for correspondence and reprints: Abhishek G. Sathe, MS; e-mail: sathe134@umn.edu. ACADEMIC EMERGENCY MEDICINE 2019;26:940–943. Funding Information: We acknowledge the ESETT Data and Safety Monitoring Board. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, or the U.S. Government.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85069833357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069833357&partnerID=8YFLogxK

U2 - 10.1111/acem.13811

DO - 10.1111/acem.13811

M3 - Letter

C2 - 31161706

AN - SCOPUS:85069833357

SN - 1069-6563

VL - 26

SP - 940

EP - 943

JO - Academic Emergency Medicine

JF - Academic Emergency Medicine

IS - 8

ER -

Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this